Valeant Pharmaceuticals International Stock Falls On Unusually High Volume (VRX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Valeant Pharmaceuticals International (NYSE: VRX) is trading at unusually high volume Thursday with 3.7 million shares changing hands. It is currently at 2.1 times its average daily volume and trading down $2.43 (-2.8%) at $83.98 as of 4 p.m. ET.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Valeant Pharmaceuticals International has a market cap of $26.2 billion and is part of the health care sector and drugs industry. Shares are up 44.6% year to date as of the close of trading on Wednesday.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. You can view the full Valeant Pharmaceuticals International Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

5 Things We Learned About Activist Investing in 2017

5 Things We Learned About Activist Investing in 2017

Valeant Pharmaceuticals Stock Still a Dog?

Valeant Pharmaceuticals Stock Still a Dog?

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)